Eric U. Yee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Eric U. Yee has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Felicia D. Allard
Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
11 shared publications - Jingxuan Yang
Hematology-Oncology, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
7 shared publications Russell G. Postier
Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
7 shared publicationsCourtney W. Houchen
6 shared publicationsHuanwen Wu
6 shared publicationsJing Yang
6 shared publications
Latest Publications
- 9 August 2024
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 192, 114909
Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice
- 9 August 2024
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 192, 114909
Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary figures from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary Figure 1. ZIP4 is correlated with EMT markers in pancreatic cancer tissue of KPC mice. Supplementary Figure 2. Knocking down ZIP4 upregulated ZO-1 and claudin-1 expression in pancreatic cancer. Supplementary Figure 3. Knocking down ZIP4 regulated mRNA of EMT markers in pancreatic cancer cell lines. Supplementary Figure 4. ZIP4 repressed ZO-1 and claudin-1 is independent with CREB. Supplementary Figure 5. Knocking down efficiency of ZO-1 and claudin-1 in AsPC-shZIP4 cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary Figure 1. ZIP4 is correlated with EMT markers in pancreatic cancer tissue of KPC mice. Supplementary Figure 2. Knocking down ZIP4 upregulated ZO-1 and claudin-1 expression in pancreatic cancer. Supplementary Figure 3. Knocking down ZIP4 regulated mRNA of EMT markers in pancreatic cancer cell lines. Supplementary Figure 4. ZIP4 repressed ZO-1 and claudin-1 is independent with CREB. Supplementary Figure 5. Knocking down efficiency of ZO-1 and claudin-1 in AsPC-shZIP4 cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary table 1 from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary table 1 showed the clinic-pathological data of patients with pancreatic adenocarcinoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 1 from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary table 1 showed the clinic-pathological data of patients with pancreatic adenocarcinoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Purpose: ZIP4 is overexpressed in human pancreatic cancer and promotes tumor growth. However, little is known about the role of ZIP4 in advanced stages of this dismal neoplasm. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by ZIP4-modulating pancreatic tumor metastasis.Experimental Design: The expression of ZIP4, ZO-1, claudin-1, and ZEB1 in human pancreatic cancer tissues, genetically engineered mouse model, xenograft tumor model, and pancreatic cancer cell lines were examined, and the correlations between ZIP4 and those markers were also analyzed. Functional analysis of ZO-1, claudin-1, and ZEB1 was investigated in pancreatic cancer cell lines and orthotopic xenografts.Results: Genetic inactivation of ZIP4 inhibited migration and invasion in pancreatic cancer and increased the expression of ZO-1 and claudin-1. Conversely, overexpression of ZIP4 promoted migration and invasion and increased the expression of ZEB1 and downregulation of the aforementioned epithelial genes. ZIP4 downregulation of ZO-1 and claudin-1 requires the transcriptional repressor ZEB1. Further analysis demonstrated that ZIP4-mediated repression of ZO-1 and claudin-1 leads to upregulation of their targets FAK and Paxillin. Silencing of ZIP4 caused reduced phosphorylation of FAK and Paxillin, which was rescued by simultaneous blocking of ZO-1 or claudin-1. Clinically, we demonstrated that ZIP4 positively correlates with the levels of ZEB1 and inversely associates with the expression of ZO-1 and claudin-1.Conclusions: These findings suggest a novel pathway activated by ZIP4-controlling pancreatic cancer invasiveness and metastasis, which could serve as a new therapeutic target for this devastating disease. Clin Cancer Res; 24(13); 3186–96. ©2018 AACR.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Purpose: ZIP4 is overexpressed in human pancreatic cancer and promotes tumor growth. However, little is known about the role of ZIP4 in advanced stages of this dismal neoplasm. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by ZIP4-modulating pancreatic tumor metastasis.Experimental Design: The expression of ZIP4, ZO-1, claudin-1, and ZEB1 in human pancreatic cancer tissues, genetically engineered mouse model, xenograft tumor model, and pancreatic cancer cell lines were examined, and the correlations between ZIP4 and those markers were also analyzed. Functional analysis of ZO-1, claudin-1, and ZEB1 was investigated in pancreatic cancer cell lines and orthotopic xenografts.Results: Genetic inactivation of ZIP4 inhibited migration and invasion in pancreatic cancer and increased the expression of ZO-1 and claudin-1. Conversely, overexpression of ZIP4 promoted migration and invasion and increased the expression of ZEB1 and downregulation of the aforementioned epithelial genes. ZIP4 downregulation of ZO-1 and claudin-1 requires the transcriptional repressor ZEB1. Further analysis demonstrated that ZIP4-mediated repression of ZO-1 and claudin-1 leads to upregulation of their targets FAK and Paxillin. Silencing of ZIP4 caused reduced phosphorylation of FAK and Paxillin, which was rescued by simultaneous blocking of ZO-1 or claudin-1. Clinically, we demonstrated that ZIP4 positively correlates with the levels of ZEB1 and inversely associates with the expression of ZO-1 and claudin-1.Conclusions: These findings suggest a novel pathway activated by ZIP4-controlling pancreatic cancer invasiveness and metastasis, which could serve as a new therapeutic target for this devastating disease. Clin Cancer Res; 24(13); 3186–96. ©2018 AACR.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary table 1 from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary table 1 showed the clinic-pathological data of patients with pancreatic adenocarcinoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 1 from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary table 1 showed the clinic-pathological data of patients with pancreatic adenocarcinoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary figures from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary Figure 1. ZIP4 is correlated with EMT markers in pancreatic cancer tissue of KPC mice. Supplementary Figure 2. Knocking down ZIP4 upregulated ZO-1 and claudin-1 expression in pancreatic cancer. Supplementary Figure 3. Knocking down ZIP4 regulated mRNA of EMT markers in pancreatic cancer cell lines. Supplementary Figure 4. ZIP4 repressed ZO-1 and claudin-1 is independent with CREB. Supplementary Figure 5. Knocking down efficiency of ZO-1 and claudin-1 in AsPC-shZIP4 cells.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figures from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Supplementary Figure 1. ZIP4 is correlated with EMT markers in pancreatic cancer tissue of KPC mice. Supplementary Figure 2. Knocking down ZIP4 upregulated ZO-1 and claudin-1 expression in pancreatic cancer. Supplementary Figure 3. Knocking down ZIP4 regulated mRNA of EMT markers in pancreatic cancer cell lines. Supplementary Figure 4. ZIP4 repressed ZO-1 and claudin-1 is independent with CREB. Supplementary Figure 5. Knocking down efficiency of ZO-1 and claudin-1 in AsPC-shZIP4 cells.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Purpose: ZIP4 is overexpressed in human pancreatic cancer and promotes tumor growth. However, little is known about the role of ZIP4 in advanced stages of this dismal neoplasm. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by ZIP4-modulating pancreatic tumor metastasis.Experimental Design: The expression of ZIP4, ZO-1, claudin-1, and ZEB1 in human pancreatic cancer tissues, genetically engineered mouse model, xenograft tumor model, and pancreatic cancer cell lines were examined, and the correlations between ZIP4 and those markers were also analyzed. Functional analysis of ZO-1, claudin-1, and ZEB1 was investigated in pancreatic cancer cell lines and orthotopic xenografts.Results: Genetic inactivation of ZIP4 inhibited migration and invasion in pancreatic cancer and increased the expression of ZO-1 and claudin-1. Conversely, overexpression of ZIP4 promoted migration and invasion and increased the expression of ZEB1 and downregulation of the aforementioned epithelial genes. ZIP4 downregulation of ZO-1 and claudin-1 requires the transcriptional repressor ZEB1. Further analysis demonstrated that ZIP4-mediated repression of ZO-1 and claudin-1 leads to upregulation of their targets FAK and Paxillin. Silencing of ZIP4 caused reduced phosphorylation of FAK and Paxillin, which was rescued by simultaneous blocking of ZO-1 or claudin-1. Clinically, we demonstrated that ZIP4 positively correlates with the levels of ZEB1 and inversely associates with the expression of ZO-1 and claudin-1.Conclusions: These findings suggest a novel pathway activated by ZIP4-controlling pancreatic cancer invasiveness and metastasis, which could serve as a new therapeutic target for this devastating disease. Clin Cancer Res; 24(13); 3186–96. ©2018 AACR.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism
Purpose: ZIP4 is overexpressed in human pancreatic cancer and promotes tumor growth. However, little is known about the role of ZIP4 in advanced stages of this dismal neoplasm. Our goal is to study the underlying mechanism and define a novel signaling pathway controlled by ZIP4-modulating pancreatic tumor metastasis.Experimental Design: The expression of ZIP4, ZO-1, claudin-1, and ZEB1 in human pancreatic cancer tissues, genetically engineered mouse model, xenograft tumor model, and pancreatic cancer cell lines were examined, and the correlations between ZIP4 and those markers were also analyzed. Functional analysis of ZO-1, claudin-1, and ZEB1 was investigated in pancreatic cancer cell lines and orthotopic xenografts.Results: Genetic inactivation of ZIP4 inhibited migration and invasion in pancreatic cancer and increased the expression of ZO-1 and claudin-1. Conversely, overexpression of ZIP4 promoted migration and invasion and increased the expression of ZEB1 and downregulation of the aforementioned epithelial genes. ZIP4 downregulation of ZO-1 and claudin-1 requires the transcriptional repressor ZEB1. Further analysis demonstrated that ZIP4-mediated repression of ZO-1 and claudin-1 leads to upregulation of their targets FAK and Paxillin. Silencing of ZIP4 caused reduced phosphorylation of FAK and Paxillin, which was rescued by simultaneous blocking of ZO-1 or claudin-1. Clinically, we demonstrated that ZIP4 positively correlates with the levels of ZEB1 and inversely associates with the expression of ZO-1 and claudin-1.Conclusions: These findings suggest a novel pathway activated by ZIP4-controlling pancreatic cancer invasiveness and metastasis, which could serve as a new therapeutic target for this devastating disease. Clin Cancer Res; 24(13); 3186–96. ©2018 AACR.
- Open Access
Hepatic pyruvate and alanine metabolism are critical and complementary for maintenance of antioxidant capacity and resistance to oxidative insult in mice
Pyruvate is a critical intermediary metabolite in gluconeogenesis, lipogenesis, as well as NADH production. As a result, there is growing interest in targeting the mitochondrial pyruvate carrier (MPC) complex in liver and metabolic diseases. However, recent in vitro data indicate that MPC inhibition diverts glutamine/glutamate away from glutathione synthesis and toward glutaminolysis to compensate for loss of pyruvate oxidation, possibly sensitizing cells to oxidative insult. Here, we explored this using the clinically relevant acetaminophen (APAP) overdose model of acute liver injury, which is driven by oxidative stress. We report that MPC inhibition does indeed sensitize the liver to APAP-induced injury in vivo, but only with concomitant loss of alanine aminotransferase 2 (ALT2). Pharmacologic and genetic manipulation of neither MPC2 nor ALT2 alone affected APAP toxicity, but liver-specific double knockout (DKO) of these proteins significantly worsened the liver damage. Further investigation confirmed that DKO impaired glutathione synthesis and increased urea cycle flux, consistent with increased glutaminolysis. Furthermore, APAP toxicity was exacerbated by inhibition of both the MPC and ALT in vitro. Thus, increased glutaminolysis and susceptibility to oxidative stress requires loss of both the MPC and ALT2 in vivo and exacerbates them in vitro. Finally, induction of ALT2 reduced APAP-induced injury.
Open AccessHepatic pyruvate and alanine metabolism are critical and complementary for maintenance of antioxidant capacity and resistance to oxidative insult in mice
Pyruvate is a critical intermediary metabolite in gluconeogenesis, lipogenesis, as well as NADH production. As a result, there is growing interest in targeting the mitochondrial pyruvate carrier (MPC) complex in liver and metabolic diseases. However, recent in vitro data indicate that MPC inhibition diverts glutamine/glutamate away from glutathione synthesis and toward glutaminolysis to compensate for loss of pyruvate oxidation, possibly sensitizing cells to oxidative insult. Here, we explored this using the clinically relevant acetaminophen (APAP) overdose model of acute liver injury, which is driven by oxidative stress. We report that MPC inhibition does indeed sensitize the liver to APAP-induced injury in vivo, but only with concomitant loss of alanine aminotransferase 2 (ALT2). Pharmacologic and genetic manipulation of neither MPC2 nor ALT2 alone affected APAP toxicity, but liver-specific double knockout (DKO) of these proteins significantly worsened the liver damage. Further investigation confirmed that DKO impaired glutathione synthesis and increased urea cycle flux, consistent with increased glutaminolysis. Furthermore, APAP toxicity was exacerbated by inhibition of both the MPC and ALT in vitro. Thus, increased glutaminolysis and susceptibility to oxidative stress requires loss of both the MPC and ALT2 in vivo and exacerbates them in vitro. Finally, induction of ALT2 reduced APAP-induced injury.
- Open Access
- 1 October 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (4) , 109897
Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease
- 1 October 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (4) , 109897
Open AccessAdenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease
- Open Access
- 26 August 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (12) , 3836-3846
Exogenous phosphatidic acid reduces acetaminophen-induced liver injury in mice by activating hepatic interleukin-6 signaling through inter-organ crosstalk
- 26 August 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (12) , 3836-3846
Open AccessExogenous phosphatidic acid reduces acetaminophen-induced liver injury in mice by activating hepatic interleukin-6 signaling through inter-organ crosstalk